Board Member
Outlook Therapeutics, Inc. (OTLK)Equibles does not estimate personal net worth.
Get an email with a short summary when Outlook Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get OTLK alertsLawrence Kenyon is recorded as CFO and Board Member at Outlook Therapeutics, Inc. (OTLK). Outlook Therapeutics, Inc. reported in an 8-K filed July 1, 2025 that Lawrence Kenyon resigned as Interim Chief Executive Officer, effective July 1, 2025. The proxy statement of Outlook Therapeutics, Inc. reports total compensation of $476,170 for Lawrence Kenyon in fiscal 2025, including a base salary of $475,000. Disclosed compensation is on record for 6 fiscal years. Lawrence Kenyon has spoken on 2 earnings calls and 1 other investor event across 1 company, most recently for Outlook Therapeutics, Inc. on August 14, 2026. Outlook Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Outlook Therapeutics, Inc. includes Robert C. Jahr (CEO and Board Member), Robert Charles Jahr (CEO and Board Member), Faisal G. Sukhtian (Chairman) and 7 others.
“Mr. Jahr replaces Lawrence Kenyon, who resigned as Interim Chief Executive Officer of the Company concurrently with Mr. Jahr’s appointment.”
“For the third quarter of fiscal 2026, we reported adjusted net loss attributable to common stockholders of $10.9 million or $0.09 per basic and diluted share compared with $15.8 million or $0.44 per basic and diluted share in the third quarter of fiscal 2025.”
“During the most recent quarter, we saw a further reduction in the balance of our outstanding convertible note. Additional conversions of the note into common stock have continued in July, and the outstanding balance is approximately $30.3 million as of today.”
“To begin, I'm very pleased to report that for the first time in the history of Outlook Therapeutics, we have secured access to the capital to potentially fully execute on our goal to receive approval for and launch ONS-5010.”
Start not stated–2025-07-01
Biotechnology · Healthcare
CFO, Board Member
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Outlook Therapeutics, Inc. (OTLK) | CEO | $475,000 | $476,170 |
| 2024 | Outlook Therapeutics, Inc. (OTLK) | CEO | $475,000 | $634,597 |
| 2021 | Outlook Therapeutics, Inc. (OTLK) | CFO | $425,000 | $2,669,214 |
| 2020 | Outlook Therapeutics, Inc. (OTLK) | CFO | $425,000 | $1,184,334 |
| 2019 | Outlook Therapeutics, Inc. (OTLK) | CEO | $425,000 | $1,863,901 |
| 2018 | Outlook Therapeutics, Inc. (OTLK) | CEO | $371,635 | $716,132 |
